CD8A and myeloid sarcoma: Despite its limitations, the CRISPR-based screening of MS models that we introduce here represents a highly versatile approach that can be easily adapted to interrogate the subsequent steps of T cell-mediated CNS pathology or could be leveraged to resolve the migration of other immune cells with critical contributions to MS pathology such as CD8+ T cells, B cells or monocytes.